56 related articles for article (PubMed ID: 31145389)
1. PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Do DV; Rhoades W; Nguyen QD
Retina; 2020 Apr; 40(4):643-647. PubMed ID: 31145389
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M
Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055
[TBL] [Abstract][Full Text] [Related]
3. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group.
Almuhtaseb H; Johnston RL; Talks JS; Lotery AJ
Eye (Lond); 2017 Nov; 31(11):1582-1588. PubMed ID: 28622328
[TBL] [Abstract][Full Text] [Related]
4. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Angermann R; Huber AL; Nowosielski Y; Salcher S; Gasser T; Seifarth C; Kralinger MT; Zehetner C
Retina; 2022 Mar; 42(3):503-510. PubMed ID: 34731094
[TBL] [Abstract][Full Text] [Related]
5. Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel.
Koh A; Lanzetta P; Lee WK; Lai CC; Chan WM; Yang CM; Cheung CMG
Asia Pac J Ophthalmol (Phila); 2017; 6(3):296-302. PubMed ID: 28379655
[TBL] [Abstract][Full Text] [Related]
6. [Application of optical coherence tomography in the assessment of the posterior lens capsule during anti-angiogenic therapy].
Alkharki L; Yusef SN; Al-Makhdar YM; Andreeva IV; Matyuschenko AG; Gerasimov AN; Budzinskaya MV
Vestn Oftalmol; 2024; 140(2. Vyp. 2):28-33. PubMed ID: 38739128
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Aqueous Humor Proteome in Patients With Age-Related Macular Degeneration.
Rinsky B; Beykin G; Grunin M; Amer R; Khateb S; Tiosano L; Almeida D; Hagbi-Levi S; Elbaz-Hayoun S; Chowers I
Invest Ophthalmol Vis Sci; 2021 Aug; 62(10):18. PubMed ID: 34406330
[TBL] [Abstract][Full Text] [Related]
8. Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration.
Spindler J; Zandi S; Pfister IB; Gerhardt C; Garweg JG
PLoS One; 2018; 13(8):e0203337. PubMed ID: 30157273
[TBL] [Abstract][Full Text] [Related]
9. Infographic: intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration (VIEW 1 and VIEW 2).
Crisostomo KGR; Dantes JKPC; Magpantay DMM; Artiaga JCM
Eye (Lond); 2023 Nov; ():. PubMed ID: 38017101
[No Abstract] [Full Text] [Related]
10. Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Leitch IM; Gerometta M; Eichenbaum D; Finger RP; Steinle NC; Baldwin ME
Ophthalmol Ther; 2024 Jul; 13(7):1857-1875. PubMed ID: 38824253
[TBL] [Abstract][Full Text] [Related]
11. Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration.
Xu X; Han N; Zhao F; Fan R; Guo Q; Han X; Liu Y; Luo G
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102176. PubMed ID: 38689803
[TBL] [Abstract][Full Text] [Related]
12. Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.
Fragiotta S; Bassis L; Abdolrahimzadeh B; Marino A; Sepe M; Abdolrahimzadeh S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674018
[TBL] [Abstract][Full Text] [Related]
13. Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Stahl A; Azuma N; Wu WC; Lepore D; Sukgen E; Nakanishi H; Mazela J; Leal S; Pieper A; Schlief S; Eissing T; Turner KC; Zhao A; Winkler J; Höchel J; Köfüncü E; Zimmermann T;
Eye (Lond); 2024 Jun; 38(8):1444-1453. PubMed ID: 38200320
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Zhu S; Fan S; Tang T; Huang J; Zhou H; Huang C; Chen Y; Qian F
Bioeng Transl Med; 2023 Nov; 8(6):e10523. PubMed ID: 38023710
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration.
Ke X; Jiang H; Li Q; Luo S; Qin Y; Li J; Xie Q; Zheng Q
Mol Ther; 2023 Nov; 31(11):3308-3321. PubMed ID: 37752703
[TBL] [Abstract][Full Text] [Related]
16. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.
Huang C; Ji L; Kaur A; Tian H; Waduge P; Webster KA; Li W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509549
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose.
Veritti D; Sarao V; Di Bin F; Lanzetta P
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242658
[TBL] [Abstract][Full Text] [Related]
18. A small molecule M1 promotes optic nerve regeneration to restore target-specific neural activity and visual function.
Au NPB; Chand R; Kumar G; Asthana P; Tam WY; Tang KM; Ko CC; Ma CHE
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2121273119. PubMed ID: 36306327
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model.
Schubert W; Terjung C; Rafique A; Romano C; Ellinger P; Rittenhouse KD
Transl Vis Sci Technol; 2022 Oct; 11(10):36. PubMed ID: 36282118
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant small-molecule promotes nerve repair and visual function recovery.
Au NPB; Kumar G; Asthana P; Gao F; Kawaguchi R; Chang RCC; So KF; Hu Y; Geschwind DH; Coppola G; Ma CHE
NPJ Regen Med; 2022 Oct; 7(1):50. PubMed ID: 36182946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
